Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk ...

A recent study published in the Journal of Affective Disorders suggests that a single dose of psilocybin may offer hope for U ...

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the ...

There are a few unmet needs in schizophrenia that can make a big difference in the prognosis and quality of life of patients.

New five-year data reinforce long-term safety and efficacy of SPRAVATO® (esketamine) in patients with inadequate response to ...

For those who live with schizophrenia, the sound of voices — voices that no one else can hear — can be an overwhelming and persistent part of daily life. But the mystery of why these hallucinations ...

The goal in treating ulcerative colitis is to reduce the inflammation, hopefully leading to remission. The two leading treatment options are medication and surgery. Approximately 70 percent of ...

a second-generation antipsychotic often used for treatment-resistant schizophrenia, also ranked low (0.12). For reference, a significant or noticeable SMD result would be anything 0.5 or higher ...

The death of a mother at the hands of her son was described as “tragic” by a Calgary judge, who found the 32-year-old not criminally responsible.